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Table 1. Comparison of Patients with and without HBV-RS
Variable With HBV-RS Without HBV-RS
P ValueCases 5 (33%) 10 (67%)
Age in years (median, range) 45 (10-46) 32(13-56) .83
Conditioning regimen
Myeloablative 4/5 (80%) 8/10 (80%) 1.0
Reduced intensity 1/5 (20%) 2/10 (20%) 1.0
aGVHD 1/5 (20%) 7/10 (70%) .12
Grade II-IV aGVHD 1/5 (20%) 1/10 (10%) 1.0
cGVHD 4/5 (80%) 8/10 (80%) 1.0
Extensive cGVHD 1/5 (20%) 1/10 (10%) 1.0
IST for cGVHD >3 years 3/5 (60%) 5/10 (50%) 1.0
Lamivudine treatment 3/5 (60%) —
Lamivudine prophylaxis* 0 5/10 (50%)
HBV vaccine after SCT 0 6/10 (60%)
Donors with
vaccination of HBV
1/5 (20%) 1/10 (10%) 1.0
Donors with
resolved HBV infection
1/5 (20%) 3/10 (30%) 1.0
RS of HBV in months
(median, range)
31 (21-101) —
Follow-up in months
(median, range)
59 (55-105) 57.5 (40-113) .37
RS indicates reverse seroconversion; HBV, hepatitis B virus; aGVHD,
acute graft-versus- host disease; cGVHD, chronic graft-versus-host dis-
ease; IST, immunosuppressive therapy; SCT, stem cell transplantation.
*Also received HBV vaccination.
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serologic monitoring, and prompt initiation of lamivu-
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Fatal Hyperacute Graft-
versus-Host Disease following
Denileukin Diftitox Treatment
for Recurrent T Cell
Lymphoma after Allogeneic
Stem Cell Transplantation
Acute graft-versus-host disease (aGVHD) causes
serious morbidity and mortality after allogeneic hema-
topoietic stem cell transplantation (HSCT). Outcomes
of therapy with glucocorticoids may be suboptimal,
and patients who do not respond to steroids have
a poor prognosis. The pathogenesis of aGVHD
involves a cytokine storm induced by pretransplanta-
tion conditioning along with dendritic cell and T cell
activation, leading to up-regulation of inflammatory
cytokines and alloreactive donor lymphocytes that
attack recipient tissues [1]. Interleukin (IL)-2 is a T
cell–derived cytokine that plays a central role in im-
mune responses by inducing activated T cell prolifer-
ation, facilitating B cell activation and proliferation,
and modulating macrophage function.
Denileukin diftitox (Ontak; Eisai Medical Re-
search, Seragen, Inc, Hopkinton, MA, License #1258)
is a recombinant fusionprotein that preferentially binds
with high affinity to T cells expressing IL-2 receptors
(CD25) [2]. Some previous reports have indicated
that denileukin diftitox depletes the CD41/CD25high
subset of T regulatory (Treg) cells, a mechanism that
has been implicated in the drug’s activity against
tumors [3]. The same subset of Treg cells suppresses
alloreactive T cells and is an important regulator of
the GVHD response [4]. It has been hypothesized
that selective binding and depletion of activated T cells
Figure 1. Photomicrographs of immunostains for CD3 (A, B, E, and F) and FOXP3 (C, D, G, and H) performed on FFPE tissue sections of skin biopsy
specimens before (A and C) and after (B and D) treatment, and colon biopsy specimens before (E and G) and after (F and H) treatment with denileukin
diftitox for posttransplantation relapsed T cell lymphoma. The skin and colon biopsy specimens exhibited histopathologic findings consistent with
GVHD, with obvious decreases in cutaneous intraepidermal and colonic lamina propria CD31 and FOXP31 T cell frequency. (Immunoperoxidase stain-
ing; original magnification 400.)
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immune function [5]. We present a case of a patient
who developed hyperacute lethal GVHD after receiv-
ing denileukin diftitox for recurrent peripheral T cell
lymphoma after HSCT.
A 53-year-old male presented in early 2006 with
diffuse lymphadenopathy. Lymph node biopsy dem-
onstrated peripheral T cell lymphoma. Based on
a multiparameter flow cytometry (MFC) immuno-
phenotyping analysis, the lymphoma cells expressedCD45 (bright), HLA-DR, CD3 (bright), CD4, CD2
(bright), and CD5 (bright), but not CD10, CD19,
CD20, or surface immunoglobulin. CD25 and
CD71 were not evaluated. A staging position emis-
sion tomography–computed tomography (PET/CT)
scan revealed extensive and diffuse activity in cervical,
thoracic, abdominal, retroperitoneal, and pelvic
lymph nodes. Bone marrow biopsy was negative for
lymphoma, and the patient was considered to have
stage III disease.
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mens (5 cycles of cyclophosphamide, vincristine, adria-
mycin, and prednisone; 2 cycles of ifosfamide, cisplatin,
and etoposide; 2 cycles of etoposide, methylpredniso-
lone, cytarabine, and cisplatin; and 4 cycles of gemcita-
bine with vinorelbine) without a durable remission and
was subsequently referred for allogeneic HSCT. In
June 2007, the patient underwent a single HLA-C–
mismatched (otherwise HLA-A–, -B–, and -DR–
matched) unrelated donor hematopoietic progenitor
cell apheresis allogeneic transplantation with a condi-
tioning regimen of fludarabine (Flu) and melphalan
(Mel). GVHD prophylaxis consisted of tacrolimus
and mycophenolate mofetil (MMF). After transplanta-
tion, the patient’s lymphadenopathy regressed. On day
61 post transplant, he was found to have clinical and ra-
diographic increase in axillary lymphadenopathy. A
rash developed over 30% of the patient’s body surface
area (BSA), which regressed with topical steroid treat-
ment. Evaluation of axillary lymph node biopsy speci-
mens revealed recurrent peripheral T cell lymphoma.
MFCanalysis demonstrated a neoplasticT cell popula-
tion with immunophenotypic features compatible with
the previous diagnosis, alongwithCD25 andCD71 ex-
pression. The patient’s immunosuppressive therapy
(tacrolimus and MMF) was tapered rapidly in an at-
tempt to elicit a graft-versus-lymphoma effect. On
day 100 posttransplantation, the patient again devel-
oped an erythematous rash involving . 90% of his
BSA. Analysis of a skin biopsy specimen demonstrated
pathological grade II aGVHD.But by day 109, the rash
resolved without lymph node regression. Because of
the CD25 expression, denileukin diftitox therapy was
initiated on day 124 posttransplantation, with the
goal ofmaximal cytoreduction in preparation for donor
lymphocyte infusion (DLI). He was started at a dose of
4.5mg/kg/dayondays 1 to 4, alongwith dexamethasone
20 mg i.v. daily. He was not on immunosuppressive
therapy at the time of initiation of denileukin diftitox
therapy. He was unable to receive day 5 of denileukin
diftitox therapy because of severe diarrhea and vomit-
ing that necessitated hospitalization. The patient un-
derwent upper gastrointestinal endoscopy and
colonoscopy with multiple biopsies, which displayed
results consistent with pathological grade III aGVHD.
The patient also developed an erythematous rash in-
volving. 90%of his BSA. Analysis of skin biopsy spec-
imens revealed pathological grade I aGVHD. He also
exhibited an elevated serum bilirubin level clinically
consistent with liver GVHD. The patient’s hyperacute
GVHD did not respond to reinitiation of immunosup-
pression, andhe died of sepsis and grade IV aGVHDon
day 144 posttransplantation. Of note, his lymphade-
nopathy had regressed by the time of death.
Immunoperoxidase stains for CD3 (polyclonal,
1:100 dilution; Dako, Carpinteria, CA), CD8 (mono-
clonal CD8/144B, 1:200 dilution; Dako), and FOXP3(monoclonal 236A/E7, 1:100 dilution; Abcam, Cam-
bridge, MA) were performed on the formalin-fixed,
paraffin-embedded (FFPE) tissue sections of the
skin and colon biopsy specimens obtained before
and after denileukin diftitox treatment. FOXP3 is
a specific marker of Treg cells and highlights these
cells in the FFPE tissue sections with a characteristic
nuclear staining pattern [6]. There was an obvious
decrease in the frequency of intraepidermal T cells
in the posttreatment biopsy specimens compared
with the pretreatment biopsy specimens (Figure 1).
There also was an obvious decrease in the frequency
of cutaneous intraepidermal and colonic lamina prop-
ria CD31 and CD81 T cells (not shown) and
FOXP31 Treg cells in the posttreatment biopsy spec-
imens (Figure 1).
The subset of CD41 cells that coexpress CD251
Treg cells suppress the expression of alloreactiveT cells
and has emerged as an important regulator of the
GVHD response. During allogeneic transplantation,
donor T cells, including CD41/CD25high regulatory
T cells, are present in unmanipulated grafts. Depletion
of either host CD41/CD25high cells before bone
marrow transplantation or donorCD41/CD25high cells
in the donor graft inoculum was shown to markedly ac-
celerateGVHD lethality in amurineGVHDmodel [4].
Denileukin diftitox may deplete the CD41/
CD25high subset of Treg cells, and this mechanism has
been implicated in the drug’s antitumor activity [3]. In
this case, posttreatment skin and colon biopsy speci-
mens exhibited a marked decreased in CD31 and
FOXP31 T cells compared with pretreatment biopsy
specimens, suggesting a role for denileukin diftitox in
depleting Treg cells, resulting in fulminant GVHD.
The patient in this case report was not on
immunosuppressive therapy at the time of denileukin
diftitox administration. A previous report noted the
efficacy of denileukin diftitox in treating steroid-
refractory aGVHD in a patient already on significant
immunosuppressive therapy [5]. It is possible that the
absence of calcineurin inhibitor and glucocorticoid
administration may have further enhanced immune
activation in this patient. Furthermore, in patients
with de novo aGVHD, denileukin diftitox along with
glucocorticoids resulted in inferior outcomes compared
with glucocorticoids alone [7].This report supports that
concept that Treg cell depletion in the absence of com-
plete T cell depletion may lead to severe aGVHD.REFERENCES
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Defining Conditioning
Regimens for BMT—
Recognition of ‘‘Regimens of
Intermediate Intensity’’
In their recent paper, Giralt et al. (2009) [1]
addressed the issue of defining the criteria for classi-
fying a reduced-intensity conditioning (RIC) regi-
men. One of the reasons for addressing this
question was to enable the transplant community to
‘‘perform adequate retrospective and prospective
analyses of different regimens,’’ and for the compari-
son of the outcome following RIC compared to non-
RIC regimens. Criteria for the definition of an RIC
regimen included in this paper were ‘‘any regimen
that does not require stem cell support for hemopoi-
etic recovery and that results in low nonhematologictoxicity and mixed donor-recipient chimerism in
a substantial population of patients in the early
posttransplantation period.’’
As part of this work the authors categorized
a number of regimens as RIC, but excluded the
BEAM regimen. This classification is in agreement
with the definitions of the European Blood and Mar-
row Transplant (EBMT) Lymphoma Working Party
(LWP) who have also classified BEAM as a non-RIC
regimen.
We became interested in using BEAM condition-
ing for allogeneic bone marrow transplantation
(BMT) because it was a regimen with a well-recog-
nized efficacy as a conditioning regimen in autolo-
gous transplantation for lymphoma with a low
toxicity profile (\5% nonrelapse mortality [NRM]).
We have previously published our initial experience
with BEAM-alemtuzumab regimen as a conditioning
regimen prior to allogeneic stem cell transplantation
(ASCT) for lymphoproliferative diseases [2]. Similar
to other RIC regimens, the NRM was \10% at 1
year, and effective long-term disease control was
achieved. This was recognized in a recent paper
from the EBMT LWP, who, in a retrospective anal-
ysis of RIC versus myeloablative transplants for
Hodgkin lymphoma (HL), included BEAM in the
RIC group because of the reported low NRM and
good clinical outcome [3]. BEAM-alemtuzumab con-
ditioning is now being used in 2 National Cancer Re-
search Network (NCRN) Lymphoma trials in the
UK (for mantle cell lymphoma and refractory Hodg-
kin disease).
Although we have no problem with the nonclassi-
fication of BEAM-alemtuzumab as an RIC regimen by
Giralt et al. [1], and we agree that although it does not
qualify under the ‘‘Champlin criteria,’’ the problem is
that by default it becomes classified as a myeloblative
regimen and grouped with regimens that have a high
NRM, particularly in lymphoma.
This same point was eloquently made in a recent
paper by Marks et al. (2008) [4], who have used a reg-
imen comprising fludarabine (Flu), melphalan (Mel)
(140 mg/m2), and BCNU (400 mg/m2) plus antithy-
mocyte globulin (ATG) as a conditioning regimen
for a variety of hematologic malignancies. These
doses of BCNU and Mel are comparable to that
used in BEAM. In their article, Marks et al. [4] also re-
ported a low NRM of 3.7% at 1 year in patients with
early disease. Furthermore, this regimen had signifi-
cant antileukemic efficacy in patients with advanced
leukemia at transplant with event-free survival (EFS)
of 40% at 5 years. These authors concluded that dis-
ease control by (Flu/Mel) was similar to myeloablative
conditioning (MAC), but with regimen-related toxic-
ities and NRM comparable to that seen with RIC
regimens.
